Aberdeen Group’s Krystal Biotech KRYS Stock Holding History

Aberdeen Group’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.34M	Sell	25,141 -5,014	-17%	-$1.5M	0.01%	611
2026 Q1	$7.79M	Sell	30,155 -9,205	-23%	-$2.45M	0.01%	629
2025 Q4	$9.7M	Sell	39,360 -20,012	-34%	-$4.21M	0.02%	616
2025 Q3	$10.5M	Sell	59,372 -49,146	-45%	-$7.36M	0.02%	594
2025 Q2	$14.9M	Buy	108,518 +71,217	+191%	+$10.5M	0.03%	495
2025 Q1	$6.73M	Sell	37,301 -19,732	-35%	-$3.32M	0.01%	645
2024 Q4	$8.93M	Buy	57,033 +13,979	+32%	+$2.48M	0.02%	532
2024 Q3	$7.84M	Sell	43,054 -318	-0.7%	-$61.3K	0.01%	566
2024 Q2	$7.96M	Buy	43,372 +4,348	+11%	+$730K	0.02%	550
2024 Q1	$6.94M	Buy	+39,024	New	+$5.42M	0.01%	608

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Aberdeen Group's KRYS Position: Q2 2026 in Review

Aberdeen Group reduced its Krystal Biotech (KRYS) stake by 17% in Q2 2026, selling an estimated $1.5M and leaving 25,141 shares worth $9.34M. The position accounts for 0.01% of the portfolio, ranked #611.

Aberdeen Group first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. The position peaked at $14.9M in Q2 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Aberdeen Group held 25,141 shares of Krystal Biotech worth $9.34M as of Q2 2026.
Aberdeen Group sold 5,014 Krystal Biotech shares in Q2 2026, an estimated $1.5M.
Krystal Biotech made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #611 holding.
Aberdeen Group first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
Aberdeen Group's Krystal Biotech position peaked at $14.9M in Q2 2025.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.